Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07437170 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Selinexor Combined With Induction Chemotherapy for Children With NUP98-positive AML

StatusActive, Not Recruiting
PhasePhase 2
Started2024-01-01
View on ClinicalTrials.gov ↗
This is a prospective, single-arm, open-label clinical study to evaluate the efficacy and safety of Selinexor combined with a standardized induction chemotherapy regimen (ZJCH-AML) for children with NUP98-fusion positive Acute Myeloid Leukemia (AML). NUP98-fusion positive AML is a high-risk subtype in pediatric patients, characterized by poor prognosis and high relapse rates under traditional chemotherapy. Preliminary research suggests that Selinexor, an XPO1 inhibitor, can selectively inhibit NUP98-driven leukemia cells. This study aims to determine if adding Selinexor to standardized chemotherapy can increase the complete remission rate and improve the overall survival for these specific high-risk patients.
Trial Details
NCT Number NCT07437170
Lead Sponsor The Children's Hospital of Zhejiang University School of Medicine
Collaborators: College of Pharmaceutical Sciences at Zhejiang University
Conditions Acute Myeloid Leukemia, Pediatric Acute Myeloid Leukemia, NUP98 Fusion-positive Acute Myeloid Leukemia
Enrollment 10 participants
Start Date 2024-01-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-27